$APYP
APPYEA, INC Stock $apyp

$apyp Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017183 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$442.0K	$430.0K	$455.0K
YoY Change	-30.39%	-5.49%
% of Gross Profit
Research & Development	$7.000K	$9.000K	$25.00K
YoY Change	-58.82%	-64.0%
% of Gross Profit
Depreciation & Amortization	$0.00	$6.000K	$6.000K
YoY Change	-100.0%	0.0%
% of Gross Profit
Operating Expenses	$449.0K	$9.000K	$480.0K
YoY Change	-31.13%	-98.13%
Operating Profit	-$449.0K	-$436.0K	-$480.0K
YoY Change	-31.13%	-9.17%
Interest Expense	$10.00K	-$20.00K
YoY Change	-133.33%
% of Operating Profit
Other Income/Expense, Net	$12.00K	-$19.00K	$16.00K
YoY Change	-140.0%	-218.75%
Pretax Income	-$342.0K	-$290.0K
YoY Change	-57.62%
Income Tax
% Of Pretax Income
Net Earnings	-$342.0K	-$289.0K	$752.0K
YoY Change	-57.62%	-138.43%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	229.6M shares	228.8M shares	218.2M shares
Diluted Shares Outstanding	234.9M shares	225.2M shares	691.8M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.00K	$100.0K
YoY Change	-73.68%
Cash & Equivalents	$47.00K	$100.0K	$79.00K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$40.00K	$20.00K
Other Receivables	$43.00K	$18.00K
Total Short-Term Assets	$90.00K	$118.0K
YoY Change	-74.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000K	$1.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$114.0K	$119.0K
YoY Change	-18.57%
TOTAL ASSETS
Total Short-Term Assets	$90.00K	$118.0K
Total Long-Term Assets	$114.0K	$119.0K
Total Assets	$204.0K	$237.0K
YoY Change	-58.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.00K	$40.00K
YoY Change	-33.33%
Accrued Expenses	$510.0K	$420.0K
YoY Change	200.0%
Deferred Revenue
YoY Change
Short-Term Debt	$233.0K	$620.0K
YoY Change	-63.59%
Long-Term Debt Due	$1.420M	$1.440M
YoY Change	4.41%
Total Short-Term Liabilities	$2.550M	$2.648M
YoY Change	8.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.550M	$2.648M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$2.546M	$2.648M
YoY Change	8.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.140M	-$4.798M
YoY Change
Common Stock	$22.00K	$22.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.328M	-$2.397M
YoY Change
Total Liabilities & Shareholders Equity	$204.0K	$237.0K
YoY Change	-58.37%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$342.0K	-$289.0K	$752.0K
YoY Change	-57.62%	-138.43%
Depreciation, Depletion And Amortization	$0.00	$6.000K	$6.000K
YoY Change	-100.0%	0.0%
Cash From Operating Activities	-$90.00K	-$97.00K	-$127.0K
YoY Change	-77.5%	-23.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.00K	$141.0K
YoY Change	-89.74%
NET CHANGE
Cash From Operating Activities	-90.00K	-$97.00K	-$127.0K
Cash From Investing Activities
Cash From Financing Activities	40.00K	$141.0K
Net Change In Cash	-50.00K	$40.00K	-$127.0K
YoY Change	400.0%	-131.5%
FREE CASH FLOW
Cash From Operating Activities	-$90.00K	-$97.00K	-$127.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	APYP	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty		usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001568969
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	APYP	Conversion Of Convertible Loan ConversionOfConvertibleLoan		usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55403
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	APPYEA, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1496846
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	16 Natan Alterman St
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Gan Yavne
CY2023Q1	dei	Entity Address Country EntityAddressCountry	IL
CY2023Q1	dei	City Area Code CityAreaCode	(800)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	674-3561
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	229565414	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60000	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	18000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	19000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	118000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	79000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	118000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	124000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	119000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	126000	usd
CY2023Q1	us-gaap	Assets Assets	237000	usd
CY2022Q4	us-gaap	Assets Assets	205000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	38000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	67000	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	423000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	340000	usd
CY2022Q4	APYP	Stock Payables StockPayables	27000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	80000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	80000	usd
CY2023Q1	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	37000	usd
CY2022Q4	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	36000	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	620000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	693000	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1436000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1528000	usd
CY2023Q1	APYP	Warrants Liability WarrantsLiability	14000	usd
CY2022Q4	APYP	Warrants Liability WarrantsLiability	24000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2648000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2768000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2648000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2768000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	22000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	21000	usd
CY2023Q1	APYP	Stock Payables StockPayables	28000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2351000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1912000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4798000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4509000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2397000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2549000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2411000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2563000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	237000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	205000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	427000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	447000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-436000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-480000	usd
CY2023Q1	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	-166000	usd
CY2022Q1	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	-1248000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-289000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	752000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-289000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	752000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.001
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.003
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.001
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.001
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	225248108	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	218246326	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	225248108	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	691754200	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2563000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	279000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-289000	usd
CY2023Q1	APYP	Stock Issued During Period Value Stock Payables StockIssuedDuringPeriodValueStockPayables	1000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	161000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2411000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2430000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2430000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	252000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	752000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1426000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1426000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-289000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	752000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	279000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	252000	usd
CY2023Q1	APYP	Financial Income Net Including Changes In Convertible Loans And Warrants FinancialIncomeNetIncludingChangesInConvertibleLoansAndWarrants	-147000	usd
CY2022Q1	APYP	Financial Income Net Including Changes In Convertible Loans And Warrants FinancialIncomeNetIncludingChangesInConvertibleLoansAndWarrants	-1235000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	74000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	96000	usd
CY2023Q1	APYP	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-21000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-97000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-127000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	141000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-4000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-127000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	60000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	206000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zhQFYFm3csH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_826_zmtAb0OQ7zB3">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AppYea, Inc. (“AppYea”, “the Company”, “we” or “us”) was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and no operating history. On November 1, 2021 the Company was redomiciled in the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock is traded on the OTC Markets, OTCQB tier, under the symbol “APYP”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse merger</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In anticipation of the reverse merger described below, on July 2, 2021, Boris Molchadsky a majority shareholder of the Company, acquired in a private transaction from the former majority shareholder consisting of two hundred and twenty-five thousand (<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20210702__20210702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BorisMolchadskyMember_zqyzi9JcQVuf" title="Number of shares acquired">225,000</span>) Shares of Series A Preferred Stock of the Company. <span id="xdx_90B_eus-gaap--PreferredStockVotingRights_c20210702__20210702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BorisMolchadskyMember_zPAD9QnpA3s" title="Preferred stock voting rights">The Series A Preferred Shares have the right to vote 1,000 to 1 as shares of common stock and are convertible into 1,500 to 1 of the shares of common stock of the Company</span>. The acquisition of the Preferred Shares provided Boris Molchadsky with control of a majority of the Company’s voting equity capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 2, 2021, the Company entered into a stock exchange agreement with SleepX Ltd., a company formed under the laws of the State of Israel (“SleepX”) and controlled by the majority shareholder of AppYea, Pursuant to the agreement, the outstanding equity capital consisting of <span id="xdx_90D_eus-gaap--SharesOutstanding_iI_pid_c20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zc2OmX0hxsDh" title="Outstanding equity capital">1,724</span> common shares of SleepX was exchanged for <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210801__20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zNP7eW5Htbf1" title="Number shares exchanged for common stock">174,595,634</span> shares of common stock of the Company, based on the agreement that determined that to SleepX shareholders will be issued common shares in the amount that will result in them holding <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SleepXLtdMember_z3y0vFom7MV1" title="Equity ownership percentage">80</span>% of the issued common shares of AppYea. As a result, SleepX became a wholly owned subsidiary of the Company. On December 31, 2021, the terms of the agreement were fulfilled; however, the issuance of the shares to SleepX shareholders, due to administrative matters, was completed in March 2022 after the Company completed a reverse stock split. The shares that were issued represented in the 2021 financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the transaction mentioned above, as of March 31, 2023, Mr. Molchadsky controls approximately <span id="xdx_90D_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BorisMolchadskyMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zpi12QeBHeT4" title="Voting interest rate">71.4</span>% of the total voting power of AppYea.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX is an Israeli research and development company that has developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and, subject to raising working capital, of which no assurance can be provided, the Company plans to start serial production in 2023. The Company will focus on further development and commercialization of the products. Its strategy will include continued investment in research and development and new initiatives in sales and marketing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX has incorporated, together with an unrelated third party, a privately held company under the laws of the State of Israel named Ta-nooma Ltd. (“Ta-nooma”). Ta-nooma has developed sleeping monitoring technology for which patent applications were filed and has no revenue from operations. Since its incorporation and as of the financial statements date, Sleepx holds <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230331__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zhFcSk1J3YAl" title="Voting interest rate">66.7</span>% of the voting interest of Ta-nooma.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to SleepX, the Company has four wholly owned subsidiaries with no active operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPYEA INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - GENERAL (cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial position</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements are presented on a going concern basis. The Company has not yet generated any material revenues, has suffered recurring losses from operations and is dependent upon external sources for financing its operations. As of March 31, 2023 and December 31, 2022, the Company has a stockholders’ deficiency of $<span id="xdx_902_eus-gaap--StockholdersEquity_iNI_di_c20230331_zv7O8VHIm7X1" title="Stockholder's deficit">2,397,000</span> and $<span id="xdx_902_eus-gaap--StockholdersEquity_iNI_di_c20221231_zUt7bUzRbM6k" title="Stockholder's deficit">2,549,000</span>, respectively. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful in obtaining the adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments for the values of assets and liabilities and their classification may be necessary in the event that the Company is no longer able to continue its operations as a “going concern”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2397000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2549000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zenRsUUBbM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUCh9TwXRN86">Use of Estimates in Preparation of Financial Statements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; letter-spacing: -0.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	206000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	268000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	120000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	140000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	80000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	80000	usd
CY2023Q1	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	37000	usd
CY2022Q4	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	36000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	272000000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	252000000	usd
CY2023Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	309000	usd
CY2022Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	297000	usd
CY2023Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	309000	usd
CY2022Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	297000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	2257000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	2492000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	153000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	526000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	18000	usd
CY2023Q1	APYP	Conversion Of Convertible Loan ConversionOfConvertibleLoan	-161000	usd
CY2023Q1	APYP	Change In Fair Value Of Convertible Loans Liability ChangeInFairValueOfConvertibleLoansLiability	156000	usd
CY2022	APYP	Change In Fair Value Of Convertible Loans Liability ChangeInFairValueOfConvertibleLoansLiability	743000	usd
CY2023Q1	us-gaap	Convertible Debt ConvertibleDebt	2093000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	2257000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	152750000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	526826000	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	The amount received during the quarter is convertible at a price equal 65% of the lowest trading price during the (10) days prior to the conversion date, with 35% discount.
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	17500	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	161473000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	8634616000	shares
CY2022	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	8634616000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10846284	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0001
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1859776	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.0001
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12706060	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0001
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9510407	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.0001
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.877	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.877	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.877	pure
CY2021Q3	APYP	Common Stock Par Or Stated Market Value CommonStockParOrStatedMarketValue	0.76
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.003	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0181	pure
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	279000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	252000	usd

Files In Submission

Name	View Source	Status
0001493152-23-017183-index-headers.html	Edgar Link	pending
0001493152-23-017183-index.html	Edgar Link	pending
0001493152-23-017183.txt	Edgar Link	pending
0001493152-23-017183-xbrl.zip	Edgar Link	pending
apyp-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
apyp-20230331_def.xml	Edgar Link	unprocessable
apyp-20230331_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
apyp-20230331_cal.xml	Edgar Link	unprocessable
apyp-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYP
APPYEA, INC Stock $apyp

2023 Q2 Form 10-Q Financial Statement

#000149315223017183 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP APPYEA, INC Stock $apyp

2023 Q2 Form 10-Q Financial Statement

#000149315223017183 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP
APPYEA, INC Stock $apyp